natgillin/translations-raw huggingface dataset:
At the end of each dosing interval, CTX reductions were partially attenuated from maximal reduction of ≥ 87% to approximately ≥ 45% (range 45-80%), reflecting the reversibility of Prolia’s effects on bone remodelling once serum levels diminish.
Na koncu posameznega intervala odmerjanja je znižanje koncentracije CTX deloma izzvenelo (od največjega znižanja ≥ 87 % na približno ≥ 45 % [razpon: 45 do 80 %]), kar kaže na to, da so vplivi zdravila Prolia na remodeliranje kosti po znižanju koncentracije v serumu reverzibilni.
At the end of infusion, wash the bag 2 or 3 times with a physiological solution using a sterile technique, in order to completely administer Zalmoxis.
Ob koncu infundiranja vrečo 2- ali 3-krat izplaknite s fiziološko raztopino s sterilno tehniko, da zagotovite uporabo celotnega zdravila Zalmoxis.
At the end of study analysis, vaccine efficacy against CIN1 associated with HPV 16/18 observed in the ATP cohort was 92.8% (95% CI: 87.1;96.4).
V analizi ob koncu študije je bila učinkovitost proti CIN1, povezanemu s HPV 16/18, ugotovljena v kohorti PP, 92,8 % (95 % IZ: 87,1;96,4).
At the end of the 24-week main treatment period, 52.3% of the lixisenatide patients achieved an HbA1c less than 7 % compared to 26.4% in the placebo group.
Ob koncu 24 tedenskega glavnega obdobja zdravljenja je HbA1c pod 7 % doseglo 52,3 % bolnikov, ki so prejemali liksenatid, in 26,4 % bolnikov, ki so prejemali placebo.
At the end of the 90-minute procedure, the medicines are flushed out of the limb using a suitable fluid.
Ob koncu tega 90-minutnega postopka se zdravili s primerno tekočino izpereta iz okončine.
At the end of the cycle (Week Four/Day 22)
Ob koncu cikla (4. teden/22. dan)
At the end of the first year (week 52 in OSLER and week 48 in OSLER-2), patients were eligible to enter the all Repatha period in which all patients could receive open-label Repatha for either another 4 years (OSLER) or 1 year (OSLER-2).
Ob koncu prvega leta (52. teden v študiji OSLER in 48. teden v študiji OSLER-2) so bili bolniki primerni za vstop v obdobje zdravila Repatha za vse, med katerim so lahko vsi bolniki odprto prejemali zdravilo Repatha ali dodatna 4 leta (OSLER) ali dodatno 1 leto (OSLER-2).
At the end of the follow-up period (actual median follow-up time of 96 months), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2,2%).
Na koncu obdobja spremljanja (dejanski mediani čas spremljanja 96 mesecev) so še trajajočo alopecijo zabeležili pri 29 bolnicah (3,9 %), ki so prejemale TAC, in pri 16 bolnicah (2,2 %), ki so prejemale FAC.
At the end of the follow-up period actual median follow-up time of 96 months), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%).
Na koncu obdobja spremljanja (dejanski mediani čas spremljanja 96 mesecev) so še trajajočo alopecijo zabeležili pri 29 bolnicah (3,9 %), ki so prejemale TAC, in pri 16 bolnicah (2,2 %), ki so prejemale FAC.
At the end of the follow-up period(actual median follow-up time of 96 months), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%).
Na koncu obdobja spremljanja (dejanski mediani čas spremljanja 96 mesecev) so še trajajočo alopecijo zabeležili pri 29 bolnicah (3,9 %), ki so prejemale TAC, in pri 16 bolnicah (2,2 %), ki so prejemale FAC.
At the end of the follow-up period, alopecia was observed to be ongoing in 29 TAC patients (4.2%) and 16 FAC patients (2.4%).
Na koncu obdobja spremljanja so še trajajočo alopecijo zabeleţili pri 29 bolnicah (4,2 %), ki so prejemale TAC, in pri 16 bolnicah (2,4 %), ki so prejemale FAC.
At the end of the main study in chronic iron overload due to blood transfusions, 53% of the patients receiving Exjade had shown a sufficient response to treatment, compared with 66% of the patients receiving deferoxamine.
Na koncu glavne študije pri kronični preobremenitvi z železom zaradi transfuzij krvi je 53 % bolnikov, ki so prejemali zdravilo Exjade, izkazalo zadosten odziv na zdravljenje v primerjavi s 66 % bolnikov, ki so prejemali deferoksamin.
At the end of the maintenance treatment in 91% of the subjects in the rotigotine arm, the optimal dose was the maximal dose allowed i.e.
Na koncu vzdrževalnega zdravljenja je bil optimalni odmerek pri 91 % bolnikov, ki so prejemali rotigotin, največji dovoljeni odmerek, tj.
At the end of the maintenance treatment in 92% of the subjects in the rotigotine arm, the optimal dose was the maximal dose allowed i.e.
Na koncu vzdrževalnega zdravljenja je bil optimalni odmerek pri 92 % bolnikov, ki so prejemali rotigotin, največji dovoljeni odmerek, tj.
At the end of the self-test, the display will show the number 0 and a green light will flash at a slow rate to indicate IONSYS is ready for application.
Ob koncu samotestiranja se na zaslonu prikaže številka »0« in zelena lučka počasi utripa, kar označuje, da je sistem IONSYS pripravljen za uporabo.
At the end of these treat-to-target trials, depending on the patient population and concomitant therapy, a 10-18% higher dose was observed in the Toujeo group than in the comparator group (Table 1 and 2).
Na koncu teh preskušanj z zdravljenjem do cilja so-odvisno od populacije bolnikov in sočasnih zdravil-v skupini z zdravilom Toujeo opažali od 10 do 18% večje odmerke kot v primerjalni skupini (preglednici 1 in 2).
At the end of this extension study, changes in msSBP from baseline were similar with aliskiren compared to enalapril (-7.63 mmHg vs. -7.94 mmHg) in the full analysis set.
Na koncu te podaljšane študije so bile spremembe srednjih vrednosti sistoličnega krvnega tlaka v sedečem položaju od izhodišča približno enake pri uporabi aliskirena v primerjavi z uporabo enalaprila (-7,63 mmHg v primerjavi z
At the end of this period of room temperature storage, the product must not be returned to refrigerated storage, but is to be used or discarded.
Po koncu tega obdobja hranjenja pri sobni temperaturi zdravila ne smete spraviti nazaj v hladilnik, ampak ga morate porabiti ali zavreči.
At the end of this period the product has to be used or discarded.
Po koncu tega obdobja morate zdravilo uporabiti ali zavreči.
At the end of this period, the product should not be put back in the refrigerator and should be disposed of.
Po tem obdobju se zdravila ne sme shraniti nazaj v hladilnik in ga je potrebno zavreči.
At the end of this study, there was no difference in overall hospitalisations for heart failure nor in mortality between bosentan- and placebo- treated patients.
Na koncu študije med bolniki, ki so jemali bosentan, in bolniki, ki so prejemali placebo, ni bilo razlike niti v skupnem številu hospitalizacij zaradi srčnega popuščanja niti v umrljivosti.
At the end of this study, there was no difference in overall hospitalisations for heart failure nor in mortality between bosentan- and placebo-treated patients.
Na koncu študije med bolniki, ki so jemali bosentan, in bolniki, ki so prejemali placebo, ni bilo razlike niti v skupnem številu hospitalizacij zaradi srčnega popuščanja niti v umrljivosti.
At the end of treatment (over 6 or 8 weeks), significant efficacy of agomelatine 25-50 mg was demonstrated in 6 out of the ten short-term double-blind placebo-controlled trials.
Na koncu zdravljenja (po 6 ali 8 tednih) so statistično značilno učinkovitost agomelatina v odmerku 25 do 50 mg dokazali v šestih od desetih kratkoročnih, dvojno slepih, s placebom nadzorovanih preskušanjih.
At the end of treatment, the doctor will slowly lower the amount of INOmax being given to you or your child, so that the circulation in the lungs is able to adjust to oxygen/air without INOmax.
Na koncu zdravljenja bo zdravnik količino zdravila INOmax, ki se bo dovajala vam ali vašemu otroku, počasi zmanjševal, da se bo obtok v pljučih lahko prilagodil kisiku/zraku brez zdravila INOmax.
At the end of week 24, 93 patients on hemodialysis whose serum phosphorus levels were controlled (<1.78 mmol/L) with Velphoro in the first part of the study, were re-randomized to continue treatment with either their week 24 maintenance dose (N=44 or a non-effective low dose control 250 mg/day, N=49) of Velphoro for a further 3 weeks.
Na koncu 24. tedna so 93 bolnikov na hemodializi, ki so jim v prvem delu študije nadzirali ravni fosforja v serumu (< 1,78 mmol/l) z zdravilom Velphoro, ponovno randomizirali, da so nadaljevali zdravljenje bodisi z vzdrževalnim odmerkom 24. tedna (N = 44) bodisi z neučinkovitim nizkim odmerkom kontrole 250 mg/dan, (N = 49) zdravila Velphoro še nadaljnje 3 tedne.
At the end of year 2 (12 months after Preotact was discontinued), there was a 12.1 mean increase in dual energy X-ray absorptiometry (DXA) spine BMD for patients who received alendronate for the second year.
Ob koncu drugega leta (12 mesecev po prekinitvi dajanja zdravila Preotact) je bilo pri bolnicah, ki so drugo leto prejemale alendronat, povprečno povečanje BMD hrbtenice 12%, izmerjeno z dvoenergijsko rentgensko absorpciometrijo (DXA - "dual energy X-ray absorptiometry").
At the end of your treatment you should return all unused capsules.
Neuporabljene kapsule morate po končanem zdravljenju vrniti.
At the event-triggered analysis the efficacy was 92.9% (96.1% CI: 79.9;98.3) against CIN2+ and 80% (96.1% CI: 0.3;98.1) against CIN3+.
Z dogodki prožena analiza je pokazala učinkovitost 92,9 % (96,1 % IZ: 79,9; 98,3) proti CIN2+ in 80 % (96,1 % IZ: 0,3;98,1) proti CIN3+.
At the event-triggered analysis the efficacy was 92.9% (96.1% CI:79.9;98.3) against CIN2+ and 80% (96.1% CI: 0.3;98.1) against CIN3+.
Z dogodki prožena analiza je pokazala učinkovitost 92,9 % (96,1 % IZ: 79,9; 98,3) proti CIN2+ in 80 % (96,1 % IZ: 0,3;98,1) proti CIN3+.
At the final analysis, median time to angiomyolipoma progression was not reached.
Ob zaključni analizi mediana časa do napredovanja angiomiolipoma ni bila dosežena.
At the final analysis, the ORR as determined by the investigator’s assessment was 46% (95% CI: 41 - 51) for the sunitinib arm and 12.0% (95% CI: 9 - 16) for the IFN-α arm (p<0.001).
Pri končni oceni je bil ORR, kot so ga določili raziskovalci, v skupini s sunitinibom 46 % (95 % IZ: 41-51) in 12,0 % (95 % IZ: 9-16) v skupini z IFN- (p < 0,001).
At the final analysis, the skin lesion response rate increased to 58.1% (95% CI: 48.1, 67.7).
Ob končni analizi se je delež bolnikov z odzivom kožnih sprememb povečal na 58,1% (95-odstotni IZ: 48,1, 67,7).
At the first occurrence, treatment should be interrupted until resolution, and then resumed at the same dose level;
Ob prvem pojavu je treba zdravljenje prekiniti, dokler neželeni učinki ne izzvenijo, in nato nadaljevati z enakim odmerkom.
At the first sign or symptom suggestive of PML, withhold Tecfidera and perform appropriate diagnostic evaluations.
Ob prvem znaku ali simptomu, ki kaže na PML, zadržite dajanje zdravila Tecfidera in izvedite ustrezno diagnostično vrednotenje.
At the first signs of recurrence (flares) of the disease symptoms, treatment should be reinitiated.
Ob prvih znakih recidiva (ponovitve) simptomov bolezni je treba zdravljenje znova začeti.
At the first signs that could suggest the syndrome (unexplained fever, dyspnoea and/or weight gain, abnormal chest auscultatory findings or radiographic abnormalities), high-dose steroids (dexamethasone 10 mg intravenously twice a day) must be immediately initiated, irrespective of the leukocyte count and continued for at least 3 days or longer until signs and symptoms have abated.
Ob prvih znakih, ki bi kazali na ta sindrom (nepojasnjena povišana telesna temperatura, dispneja in/ali pridobivanje telesne mase, nenormalni avskultatorni izvidi ali radiografske anomalije prsnega koša), morate takoj začeti dajati visoke odmerke steroidov (deksametazon 10 mg intravensko dvakrat na dan) in z njimi nadaljevati vsaj 3 dni ali dlje, dokler bolezenski znaki ne izginejo, ne glede na število levkocitov.
At the follow-up visit 1 to 3 days after the second injection of each treatment cycle, the trained physician should perform a penile modeling procedure on the flaccid penis to stretch and elongate the treated plaque that Xiapex has disrupted.
Ob kontrolnem obisku 1 do 3 dni po drugi injekciji vsakega cikla zdravljenja mora usposobljen zdravnik opraviti postopek modeliranja penisa pri mlahavem penisu, da zdravljeni plak, ki ga je zdravilo Xiapex prekinilo, razteza in podaljša.
At the follow-up visit approximately 24 – 72 hours after injection, determine if the contracture has resolved.
Na kontrolnem pregledu približno 24 – 72 ur po injiciranju preverite, ali je kontraktura odpravljena.
At the follow-up visit approximately 24 – 72 hours after injection, it should be determined if the contracture has resolved.
Na kontrolnem obisku približno 24 – 72 ur po injiciranju je treba preveriti, ali je kontraktura odpravljena.
At the fourth occurrence
Ob četrtem pojavu
At the highest dosage levels, minor effects on indicators of liver and kidney function were seen together with occasional reduction in liver weights.
Pri največjih odmerkih so opazili manjše učinke na pokazatelje jetrne in ledvične funkcije ter občasno zmanjšanje teže jeter.
At the highest tested doses, the systemic exposures (based on AUC) to etravirine were 0.6-fold (mice) and between 0.2- and 0.7-fold (rats), relative to those observed in humans at the recommended therapeutic dose (200 mg b.i.d.).
Pri najvišjih preskušanih odmerkih je bila sistemska izpostavljenost etravirinu (na osnovi AUC) 0,6-kratna (miši) in 0,2-0,7-kratna (podgane), glede na izpostavljenosti opažene pri ljudeh pri priporočenem terapevtskem odmerku (200 mg b.i.d.).
At the initial visit, the patients’ clinical status, social situation, and alcohol consumption pattern were evaluated (based on patient reporting).
Pri začetnem obisku so bili ocenjeni klinično stanje, socialni položaj in vzorec uživanja alkohola bolnikov (na podlagi bolnikovega poročanja).
at the injection site, skin reactions, phlebitis (inflammation of the vein) or swelling
kožne reakcije, flebitis (vnetje vene) ali otekanje
at the injection site, skin reactions, phlebitis (inflammation of the vein) or swelling
kožne reakcije, flebitis (vnetje vene) ali otekanje na mestu injiciranja,
at the injection site, skin reactions, phlebitis (inflammation of the vein) or swelling
kožne reakcije, flebitis (vnetje vene) ali otekanje na mestu injiciranja;
at the injection site, skin reactions, phlebitis (inflammation of the vein) or swelling
na mestu injiciranja, kožne reakcije, flebitis (vnetje vene) ali otekanje
At the injection site: erythema, pain, swelling
na mestu injiciranja: eritem, bolečina, oteklost
At the injection site: pain, redness, hardness, swelling.
Na mestu injiciranja: bolečina, pordelost, otrdelost, oteklina.
At the injection site: pain, redness, swelling, hardness.
Na mestu injiciranja: bolečina, pordelost, oteklina, otrdelost.
At the injection site: pain, swelling, erythema
na mestu injiciranja: bolečina, oteklost, eritem
At the injection site: redness, hardness, swelling, itching and pain.
Na mestu injiciranja: pordelost, otrdelost, otekanje, srbenje in bolečina.
at the injection site; skin reactions, inflammation of the vein or swelling
na mestu vboda, kožne reakcije, vnetje žil ali otekanje;
At the intended dose, pharmacokinetic parameters are not significantly affected by gender.
Pri predvidenem odmerku spol ne vpliva bistveno na farmakokinetične parametre zdravila.
At the last evaluation, 19 of 22 patients (86%) achieved eGFR improvement of ≥ 15 mL/min/1.73 m2 from baseline.
Pri zadnjem ocenjevanju je 19 od 22 bolnikov (86 %) doseglo izboljšanje eGFR za ≥ 15 ml/min/1,73 m2 od izhodišča.
At the last evaluation, 57% of infliximab-treated patients remained anti-dsDNA positive.
Ob zadnji oceni je bilo 57 %bolnikov, zdravljenih z infliksimabom, še vedno pozitivnih na anti-dsDNA.
At the last follow-up, clinical signs were improved in 74/134 patients (55.2%), hypertension in 36/90 patients (40), hypokalaemia in 10/26 patients (38.4%), and diabetes mellitus in 23/39 patients (59%).
Ob zadnjem sledenju so se klinični znaki izboljšali pri 74/134 bolnikov (55,2 %), hipertenzija pri 36/90 bolnikov (40 %), hipokaliemija pri 10/26 bolnikov (38,4 %) in sladkorna bolezen pri 23/39 bolnikov (59 %).
At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine 100 units/ml group and a mean decrease of 0.8 kg in the standard care group.
Na zadnjem obisku med zdravljenjem je bilo povprečno povečanje telesne mase od izhodišča v skupini z insulinom glarginom 100 enot/ml 1,4 kg in povprečno zmanjšanje v skupini s standardno oskrbo 0,8 kg.
At the last visit, 78 patients (49.3%) were controlled, 37 patients (23.4%) had partial control with at least 50% decrease of UFC (without normalisation), and 43 patients (27.2%) had unchanged UFC levels.
Ob zadnjem obisku je bila bolezen pri 78 bolnikih (49,3 %) nadzorovana, pri 37 (23,4 %) delno nadzorovana z vsaj 50-odstotnim znižanjem ravni prostega kortizola v urinu (brez normalizacije), 43 bolnikov (27,2 %) pa je imelo nespremenjene ravni prostega kortizola v urinu.
At the low chemical concentrations present in Amyvid, florbetapir (18F) does not have any detectable pharmacological activity.
Ker je florbetapir (18F) v zdravilu Amyvid prisoten v nizki kemijski koncentraciji, nima zaznavne farmakološke aktivnosti.
At the low chemical concentrations present in Neuraceq, florbetaben (18F) does not have any detectable pharmacodynamic activity.
Ker je [18F]florbetaben v zdravilu Neuraceq prisoten v nizki kemijski koncentraciji, nima zaznavne farmakodinamične aktivnosti.
At the low concentrations present in VIZAMYL, flutemetamol (18F) has no detectable pharmacodynamic activity.
Pri nizkih koncentracijah, ki so prisotne v zdravilu VIZAMYL, za flutemetamol (18F) ni mogoče zaznati farmakodinamičnega delovanja.
At the lowest tested doses in the carcinogenicity studies, the systemic exposures (based on AUC) to rilpivirine were 21-fold (mice) and 3-fold (rats), relative to those observed in humans at the recommended dose (25 mg once daily).
Pri najnižjih odmerkih, ki so jih preizkušali v študijah kancerogenosti, je bila sistemska izpostavljenost rilpivirinu (na podlagi AUC) pri miših 21-krat večja, pri podganah pa 3-krat večja od izpostavljenosti pri ljudeh glede na priporočen odmerek (25 mg enkrat na dan).
At the mediam follow up time of 10 years and 5 months, TAC-treated patients had a 16.5% reduction in the risk of relapse compared to those treated with FAC (hazard ratio = 0.84, 95% CI (0.65-1.08, p=0.1646).
Po medianem spremljanju 10 let in 5 mesecev so imele prejemnice TAC 16,5 % manjše tveganje za recidiv kot prejemnice FAC (razmerje ogroženosti = 0,84, 95 % IZ 0,65-1,08, p = 0,1646).
At the median follow-up 77 months, significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
Po mediano 77 mesecih spremljanja je bilo dokazano, da je preživetje brez bolezni v kraku TAC značilno daljše kot v kraku FAC.
At the median follow-up 77 monthssignificantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
Po mediano 77 mesecih spremljanja terapije je bilo preživetje brez bolezni v kraku TAC dokazano značilno daljše kot v kraku FAC.
At the median follow-up time of 77 months overall survival (OS) was longer in the TAC arm with TAC-treated patients having a 24% reduction in the risk of death compared to FAC (hazard ratio = 0.76, 95% CI (0.46-1.26, p = 0.29).
Po mediano 77 mesecih spremljanja je bilo tudi celokupno preživetje v kraku TAC daljše: tveganje za smrt je bilo med prejemnicami TAC za 24 % manjše kot med prejemnicami FAC (razmerje ogroženosti = 0,76, 95 % IZ 0,46-1,26, p = 0,29).
At the median follow-up time of 77 months, overall survival (OS) was longer in the TAC arm with TAC-treated patients having a 24% reduction in the risk of death compared to FAC (hazard ratio = 0.76, 95% CI (0.46-1.26, p=0.29).
Po mediano 77 mesecih spremljanja je bilo dokazano, da je bilo celotno preživetje v kraku TAC daljše: tveganje smrti je bilo med prejemnicami TAC za 24 % manjše kot med prejemnicami FAC (razmerje ogroženosti = 0,76, 95 % IZ (0,46-1,26), p = 0,29).
At the median follow-up time of 77 months, significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
Po mediano 77 mesecih spremljanja terapije je bilo preživetje brez bolezni je bilo v kraku TAC dokazano značilno daljše kot v kraku FAC.
At the median follow-up was time of 77 months significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
Po mediano 77 mesecih spremljanja je bilo dokazano, da je preživetje brez bolezni v kraku TAC značilno daljše kot v kraku FAC.
At the median follow-up was time of 77 months, significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
Po mediano 77 mesecih spremljanja je bilo dokazano, da je preživetje brez bolezni v kraku TAC značilno daljše kot v kraku FAC.
At the menopause, a woman’s ovaries stop producing the female hormone oestrogen, which helps keep bones healthy.
Pri ženski po menopavzi jajčniki ne tvorijo več ženskega hormona estrogena, ki pomaga ohranjati kosti zdrave.
At the menopause, a woman’s ovaries stop producing the female hormone, oestrogen, which helps to keep her skeleton healthy.
V menopavzi jajčniki prenehajo proizvajati ženski hormon estrogen, ki ženskam pomaga ohranjati zdravo okostje.
At the menopause, the ovaries stop producing the female hormone, oestrogen, which helps to keep a woman’s skeleton healthy.
V menopavzi jajčniki prenehajo proizvajati ženski hormon estrogen, ki ženskam pomaga ohranjati zdravo okostje.
At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP12) which is responsible for the intracellular accumulation of the compound.
Kaže, da do učinkov takrolimusa na molekulski ravni prihaja preko vezava na citosolno beljakovino (FKBP12), ki je odgovorna za njegovo znotrajcelično kopičenje.
At the No Observed Adverse Effect Level (NOAEL) of 0.5 mg/eye in monkeys the systemic exposure was 42- and 56-fold higher based on Cmax and AUC, respectively.
Glede na NOAEL (No Observed Adverse Effect Level) je bila sistemska izpostavljenost pri opicah pri odmerku 0,5 mg/oko 42-krat večja glede na Cmax oziroma 56- krat večja glede na AUC.
At the no-effect level for these findings, systemic exposure levels (AUC) were, in rats, approximately 1.5–fold the expected human exposure levels in females and 0.8-fold in males, and in mice, approximately 0.8-fold the expected human exposure levels in both males and females.
Raven brez opaženega učinka ('the no-effect level') ter ravni sistemske izpostavljenosti (AUC) so bile za te ugotovitve pri podganah približno 1,5-kratnik vrednosti ravni, pričakovanih za človeka tako pri moških kot pri ženskah, ter pri miših približno 0,8-kratnik vrednosti ravni, pričakovanih za človeka, tako pri moških kot pri ženskah.
At the NOEL dose (3mg/kg/day), the AUCs for anagrelide and the metabolites BCH24426 and RL603 were 14, 2 and 2-fold higher than the AUC in humans administered an oral dose of anagrelide 2mg/day.
(3 mg/kg/dan) so bile AUC za anagrelid oziroma presnovka RL603 in BCH24426 14-, 2- oziroma 2- krat večje kot AUC pri ljudeh, ki so jim dajali peroralni odmerek anagrelida 2 mg/dan.
At the onset of symptoms or signs consistent with hepatic injury or if abnormal ALT or AST increases are detected during treatment, Jinarc administration must be interrupted and repeat tests including ALT, AST, BT and alkaline phosphatase (AP) must be obtained as soon as possible (ideally within 48- 72 hours).
Ob nastopu simptomov ali znakov, ki so enaki kot pri poškodbi jeter, ali če se med zdravljenjem zaznajo nenormalne ravni ALT ali AST, je treba dajanje zdravila Jinarc prekiniti in teste čim prej ponoviti, vključno z ALT, AST, skupnim bilirubinom in alkalno fosfatazo (AF) (idealno v 48– 72 urah).